|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/10 | |
| A61K 38/35 | |||
| A61P 35/00 | |||
| A61P 25/00 | |||
| A61P 17/00 | |||
| A61P 3/00 | |||
| A61P 3/02 | |||
| A61P 17/06 | |||
| A61P 27/00 | |||
| A61P 11/00 | |||
| A61P 1/00 | |||
| A61P 15/00 | |||
| A61P 19/00 | |||
| A61P 43/00 |
| (11) | Number of the document | 2187901 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08802082.1 |
| Date of filing the European patent application | 2008-09-09 | |
| (97) | Date of publication of the European application | 2010-05-26 |
| (45) | Date of publication and mention of the grant of the patent | 2012-08-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2008/007522 |
| Date | 2008-09-09 |
| (87) | Number | WO 2009/039978 |
| Date | 2009-04-02 |
| (30) | Number | Date | Country code |
| 07017750 | 2007-09-11 | EP |
| (72) |
BEVEC, Dorian, DE
CAVALLI, Fabio, CH
CAVALLI, Vera, CH
BACHER, Gerald, DE
|
| (73) |
Mondobiotech Laboratories AG,
Herrengasse 21, 9490 Vaduz,
LI
|
| (54) | Neuropeptide El optionally combined with ACTH (7-38) for use in anti-angiogenic therapy |
| Neuropeptide El optionally combined with ACTH (7-38) for use in anti-angiogenic therapy |